Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma - Wikidata - awgldk - TriplyDB

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

http://www.wikidata.org/entity/Q28209540

about

sameAs

A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score Concomitant non-Hodgkin's lymphoma in colon and liver: report of a rare case and review of literature Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma.De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association.Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.Primary pulmonary lymphoma in a patient with advanced AIDS Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma.Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.Genetic lesions in diffuse large B-cell lymphomas Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study.Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities.Gastrointestinal lymphoproliferative disorders.Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.Quantitative image analysis in the assessment of diffuse large B-cell lymphoma.B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3 Primary diffuse large B-cell lymphoma of the ascending colon.A Study of the Newer Prognostic Markers in Diffuse Large B Cell Lymphomas.Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Prognostic impact of C-REL expression in diffuse large B-cell lymphoma.Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma.Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor.Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials

P2860

Q24653343-EEECA636-25B8-40ED-BBDD-F9609FB3D230 Q28082415-D22D09DC-47D2-4E90-BF05-1E4704CFF90E Q28253182-97A65C11-04F5-477B-875E-FFB1F3055169 Q28256567-3E6B63E5-AFAB-471E-BC9A-BF156D4B9FED Q30240133-31E49542-E814-4735-9A47-AC1A24032079 Q30478328-90515558-C2DB-4EF2-9DE2-5E3D252111B3 Q33629575-8FB84E15-586D-4EBD-A238-2CDF5A794394 Q34277652-97EA3050-2437-4235-9404-F85C78AC2DFC Q34314938-AC4EE811-66EB-403B-A85E-DF99DC391B41 Q34574781-5D489805-6430-4187-87B0-D9FE6FC2D2C2 Q34695303-0AFF444C-87F0-44ED-B1F8-A44EF1562AB8 Q34768232-1FCBAD23-C67F-4F22-A31F-E53CCC27BF95 Q35193836-D4C5DB24-0B09-45BC-BE34-053CAC824518 Q35590607-E7BF265E-8948-4B87-A955-6E1205F25C83 Q35628884-2F6824D3-131B-4B0F-8610-6C592103274E Q35720027-E7F92DE4-7381-4DAB-B05D-58C926A702D6 Q35849663-CF1DB51B-6F88-49FD-ADE3-F10A65294745 Q35932225-DF095283-0C5C-4BC4-8DCB-AA43FC60FDE9 Q35974341-DBEBAD05-3CCC-4637-B305-095C88F63853 Q35978570-B0A58A5C-058E-4A5B-B188-ABC31BBB649A Q36171783-7D7A4E19-ECDF-4E63-89E8-9AAF4194F291 Q36194645-13B2F52A-DA7A-4B3F-9D02-11BE5A759385 Q36559885-0A2C4543-D74F-4A5C-A072-AC80C9453070 Q36622610-7C4CECD9-44D3-4CC5-AF12-173696876A46 Q36699528-E0C5DC47-418A-424A-98C3-57260BA8EDDB Q36752014-07CE2A33-BBE3-45E5-B918-88626FD6D25C Q36757502-43142F4E-A9A3-4B45-AD35-2405E109F402 Q36965870-45B267E8-F2CE-4E4C-BE81-6356F251C332 Q36971217-6C21800E-964C-44D8-A721-3190E6DD7775 Q37034634-D15E4271-BE50-41CE-B752-930AF49E2A50 Q37037156-3FD0EE7C-DC98-4BFE-BB3D-123A38F23A9D Q37045955-D8E85B5A-51EC-4F4D-A70F-856087A95147 Q37132882-C2FEE5D1-2CC5-4CFD-8111-FD01ABDE1AF3 Q37212700-2A1DA83E-138C-439D-A57E-534733E9A975 Q37269036-A23DF1E5-90B6-4DE9-92B3-A19B56A94F83 Q37280910-896B6D86-D727-4EF2-B38F-E5E5AFF56F70 Q37300030-85BE0D53-6064-466E-9E1E-2EA8B8435AD9 Q37313308-1A818F0E-418C-45A6-B036-950DB39054D6 Q37330181-F0585C7B-381D-4329-BF97-47B720525846 Q37406798-E457939B-0B55-44F6-BAC4-70A200CD9CBE

P2860

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

http://www.wikidata.org/entity/Q28209540

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@ast

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@en

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@nl

type

label

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@ast

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@en

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@nl

prefLabel

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@ast

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@en

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@nl

P1433

Q28209540-9D3EA6A3-FD5D-4B6D-8160-C32E34B96707

P1476

Q28209540-DDF9FB1C-4CC6-40E8-B4C1-64271740606F

P2093

Q28209540-0DD1EA1C-5139-48D7-8052-9FE3E5CC6626

Q28209540-2B50DDD7-CB5E-422F-920A-2A3D3E29539A

Q28209540-880A26AD-FCA3-4D2A-A1AF-16276AC90C79

Q28209540-AF5ECAB6-6566-49CF-B0F6-9CF06EDB563B

Q28209540-EFBD7201-3ADF-4FCD-8826-1DFB0568E587

Q28209540-FDF963EE-18AD-4802-BC2C-31B2C4A599B4

P304

Q28209540-7FCA25D1-1FC3-4EB9-977F-FCA543EF1A01

P31

Q28209540-09C44638-E89D-4F12-BBFA-CBBA44827912

P356

Q28209540-786B8A25-6229-440C-9AA9-00A342A39C44

P407

Q28209540-0565CCBB-D056-4B73-8039-778EDC8E730B

P433

Q28209540-FC4354A6-6649-44B7-BDED-CCA35DA84F0D

P478

Q28209540-E61E7234-FE26-45E1-8FD3-CFF7FEE784B2

P50

Q28209540-096C3B10-E22B-4ABC-959A-38273E273B45

Q28209540-186D9125-2330-4705-BE49-0A7B5B112F54

Q28209540-1AA92E5C-42E3-4CA5-9204-6C57235455D0

Q28209540-1F921BD9-94CD-4D21-A807-C4AC6BD5A0DC

P577

Q28209540-2EF1434E-A6F5-4454-ABA6-DBD28ABD1041

P5875

Q28209540-A4871665-2BA6-4F69-AA08-483B08527031

P698

Q28209540-A00729BC-E4F5-4ECC-BC65-B1EE23041A5D

P921

Q28209540-929BBAC7-293F-4535-8D45-E50B80CFC278

P356

BLOOD-2002-04-1286

P1433

P1476

Clinical impact of the differe ...... diffuse large B-cell lymphoma

@en

P2093

Antonio Martínez

http://www.w3.org/2001/XMLSchema#string

Armando López-Guillermo

http://www.w3.org/2001/XMLSchema#string

Emili Montserrat

http://www.w3.org/2001/XMLSchema#string

Lluís Colomo

http://www.w3.org/2001/XMLSchema#string

María Perales

http://www.w3.org/2001/XMLSchema#string

Susana Rives

http://www.w3.org/2001/XMLSchema#string

P304

78-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-04-1286

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Brunangelo Falini

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5328988

http://www.w3.org/2001/XMLSchema#string

P698

12393466

http://www.w3.org/2001/XMLSchema#string

P921